Empaveli Approved for C3G and Primary IC-MPGN
C3G and primary IC-MPGN are rare kidney diseases affecting approximately 5000 people in the US, particularly adolescents or young adults. They often lead to kidney failure requiring dialysis or kidney transplant.
In the recently released Phase 3 VALIAN Trial 52-week results, patients receiving pegcetacoplan achieved and maintained a significant reduction in proteinuria over baseline, with a mean urine protein-to-creatinine ratio change at week 26 of -68.1% and at week 52 of -67.2%.
In addition, the pegcetacoplan group showed a reduction in estimated glomerular filtration rate levels of -1.2 mL/min/1.73 m2 at week 26 and -3.7 mL/min/1.73 m2 at week 52.
The most common adverse reactions were infusion site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea, according to a company press release.
The product will carry a black box warning stating, 'Empaveli, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B.
'Because of the risk of serious infections caused by encapsulated bacteria, Empaveli is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.'
Kathleen Dallessio is the Senior Editor for Diabetes & Endocrinology and Nephrology at Medscape Medical News.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced that it is monitoring a safety issue with Boston Scientific Corporation's ENDOTAK RELIANCE defibrillation leads, which are used with implantable cardioverter-defibrillators to prevent sudden cardiac death. Earlier this year, the company sent a letter to healthcare providers on July 24, warning that calcification of the leads' expanded polytetrafluoroethylene/ePTFE coating could lead to a gradual increase in low-voltage shock impedance/LVSI. This can reduce the effectiveness of life-saving shocks and even result in patient death. A surgeon examining a patient's brain in an operating room, paramedics nearby. The affected leads were manufactured and distributed between 2002 and 2021 and are no longer available. As of July 24, Boston Scientific had reported 386 serious injuries and 16 deaths linked to this issue. The FDA has categorized this as a potentially high-risk problem and is actively reviewing data to determine further regulatory action. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has 2 segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
What to Know TODAY: Woman Who Lost 240 Pounds Shares Question That Helped Her Eat Better
The Food and Drug Administration has issued an alert over certain cookware due to risk of lead leaching into food. Plus, a woman who dropped 240 pounds after taking up running shares her weight loss tips, and a dentist offers a simple trick to help you stop clenching your jaw. Here's what to know for Friday, Aug. 15, 2025. FDA Issues Alert Over Cookware Due to Risk of Lead Leaching Into Food Home cooks should take a close look at their pots, pans and kitchen utensils due to a risk of 'significant levels of lead' leaching into food, according to the U.S. Food and Drug Administration. The agency recently posted an alert regarding a Kada/Karahi Tiger White pure aluminum bowl because of associated health risks discovered during recent testing and shared which other products may be higher risk for leaching lead. Here's what to know. Woman Loses 240 Pounds. 1 Simple Question Helped Her Stop 'Eating Really Bad' Samantha Hager weighed nearly 380 pounds when she vowed to lose weight after visiting an amusement park with her stepsons and couldn't fit on the rides. She took up running — an activity she hated — and made changes to her diet, dropping 240 pounds in the process. Hager, 29, shares her tips for eating healthier, including the question she asked herself when she was tempted by junk food. Dentist Shares 1 Simple Breathing Exercise to Stop Clenching Your Jaw In Expert Tip of the Day, a dentist reveals how in less than a minute, you can relax your jaw muscles with this simple trick. Award-Winning Hair Tools for Combating Hair Loss, Styling Unruly Strands and More — Starting at $12 Shop TODAY's first-ever Hair Awards have landed! Staffers spent weeks curling, straightening, teasing and combing their hair to find the best tools. Consider these the best of the best. Chicken Parmesan Burgers These burgers from cookbook author Anna Francese Gass have all the flavors of a classic chicken Parm in a juicy sandwich. Since they're made on a sheet pan, cleanup is a breeze. Get the recipe! This article was originally published on
Business Insider
8 hours ago
- Business Insider
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
Tonix Pharmaceuticals (TNXP) Holding Corp. announced that the FDA approved Tonmya for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (greater than or equal to30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. Elevate Your Investing Strategy:
